Time Exposure and Fat Mass Reduction Drive Trimethylamine N-Oxide Modulation During a Very-Low-Energy Ketogenic Therapy (VLEKT) in Women with Obesity

<b>Background/Objectives</b>: Trimethylamine N-oxide (TMAO) is a gut microbiota-derived metabolite increasingly recognized as a pro-atherogenic factor and a biomarker of cardiometabolic risk. Dietary patterns and adiposity are key modulators of circulating TMAO levels; however, evidence on the impact of very-low-energy ketogenic therapy (VLEKT) on TMAO metabolism, particularly in women with obesity, remains limited. This study aimed to investigate the effects of VLEKT on circulating TMAO concentrations, with specific focus on treatment duration and body composition (BC) changes. <b>Methods</b>: This study included 43 adult women with obesity eligible for VLEKT based on meal replacements. Anthropometric measurements and BC were assessed using standardized protocols and bioelectrical impedance analysis at baseline and post-intervention. Serum TMAO concentrations were quantified by validated HPLC-ESI-MS/MS. <b>Results</b>: After VLEKT, participants exhibited significant reductions in body weight, BMI, waist girth, fat mass (FM), and circulating TMAO levels. Greater reductions in TMAO were observed in women with longer ketogenic exposure and more pronounced FM loss. Changes in TMAO levels correlated negatively with VLEKT duration and positively with FM variations. In multivariate models, treatment duration and FM reduction emerged as independent predictors of TMAO decrease. A Receiver Operating Characteristic (ROC) analysis identified a FM reduction ≥14.25% as the optimal threshold associated with clinically relevant TMAO lowering. <b>Conclusions</b>: VLEKT reduces circulating TMAO levels in women with obesity. This effect appears to be primarily driven by the duration of ketogenic exposure and the magnitude of FM loss, rather than total weight reduction alone, highlighting the relevance of BC-targeted interventions in modulating gut microbiota-derived cardiometabolic risk markers.

Authors

Institutions

Publication Details

Journal
Metabolites
Published
2026-02-24
DOI
https://doi.org/10.3390/metabo16030150
Primary Topic
Gut microbiota and health
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Time Exposure and Fat Mass Reduction Drive Trimethylamine N-Oxide Modulation During a Very-Low-Energy Ketogenic Therapy (VLEKT) in Women with Obesity

Giuseppe Annunziata, Maria Maisto, Martina Galasso, V. Piccolo et al.
Metabolites
Gut microbiota and health
article

Time Exposure and Fat Mass Reduction Drive Trimethylamine N-Oxide Modulation During a Very-Low-Energy Ketogenic Therapy (VLEKT) in Women with Obesity

Giuseppe Annunziata, Maria Maisto, Martina Galasso, V. Piccolo, Ludovica Verde, Luigi Barrea, Gian Carlo Tenore, Annamaria Colao, Giulia De Alteriis, Giovanna Muscogiuri
article en

Abstract

<b>Background/Objectives</b>: Trimethylamine N-oxide (TMAO) is a gut microbiota-derived metabolite increasingly recognized as a pro-atherogenic factor and a biomarker of cardiometabolic risk. Dietary patterns and adiposity are key modulators of circulating TMAO levels; however, evidence on the impact of very-low-energy ketogenic therapy (VLEKT) on TMAO metabolism, particularly in women with obesity, remains limited. This study aimed to investigate the effects of VLEKT on circulating TMAO concentrations, with specific focus on treatment duration and body composition (BC) changes. <b>Methods</b>: This study included 43 adult women with obesity eligible for VLEKT based on meal replacements. Anthropometric measurements and BC were assessed using standardized protocols and bioelectrical impedance analysis at baseline and post-intervention. Serum TMAO concentrations were quantified by validated HPLC-ESI-MS/MS. <b>Results</b>: After VLEKT, participants exhibited significant reductions in body weight, BMI, waist girth, fat mass (FM), and circulating TMAO levels. Greater reductions in TMAO were observed in women with longer ketogenic exposure and more pronounced FM loss. Changes in TMAO levels correlated negatively with VLEKT duration and positively with FM variations. In multivariate models, treatment duration and FM reduction emerged as independent predictors of TMAO decrease. A Receiver Operating Characteristic (ROC) analysis identified a FM reduction ≥14.25% as the optimal threshold associated with clinically relevant TMAO lowering. <b>Conclusions</b>: VLEKT reduces circulating TMAO levels in women with obesity. This effect appears to be primarily driven by the duration of ketogenic exposure and the magnitude of FM loss, rather than total weight reduction alone, highlighting the relevance of BC-targeted interventions in modulating gut microbiota-derived cardiometabolic risk markers.

MetabolitesVol. 16(3)
University of Arizona (US), San Raffaele University of Rome (IT), Pegaso University (IT), University of Naples Federico II (IT)
Good health and well-being
Openalex Percentile: Top 44%
Gut microbiota and health
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.